Search
Daclizumab
go.drugbank.com/drugs/DB00111ApprovedInvestigationalWithdrawnDespite being approved for use, Zinbryta (daclizumab)'s complex pre-existing safety profile consisting of its restricted availability through a Risk Evaluation and Mitigation Strategy program [L1738] and … This withdrawal was concurrent to the European Medicines Agency announcement of a recall owing to 12 worldwide reports of serious inflammatory brain disorders associated with the use of Zinbryta (daclizumab
Categories: Interleukin-2 Receptor Antagonist, Interleukin-2 Receptor Blocking AntibodyProtamine sulfate
go.drugbank.com/drugs/DB09141ApprovedInvestigationalSince it's earliest discovery in salmon rine sperm heads in the late 1800's to its formal introduction via US FDA approval in 1939, protamine sulfate has occupied an important therapeutic niche as perhaps … As a consequence, whenever protamine sulfate use is clinically considered, careful consideration must be given as to whether the use of the agent could decrease the safety of the procedure or worsen the
Products: PROLFAT 50 MG/5 ML IV ENJEKSİYONLUK ÇÖZELTİ, 1 ADET, PAMINTU 10 MG/ML ENJEKSIYONLUK ÇÖZELTI IÇEREN FLAKON,5 ML 1 ADETMM-093
go.drugbank.com/drugs/DB05512InvestigationalCurrent studies are assessing MM-093’s potential to improve the treatment of autoimmune disease. … MM-093 is a recombinant version of human alpha-fetoprotein (hAFP), an immunomodulatory serum protein normally produced at very high levels by the fetus and present in low levels in the blood of adults
Sarecycline
go.drugbank.com/drugs/DB12035ApprovedInvestigationals Seysara (sarecylcine) as a new first in class narrow spectrum tetracycline derived oral antibiotic for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].
Categories: P-glycoprotein inhibitorsAbdavomeran
go.drugbank.com/drugs/DB15695Investigational[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding the receptor-binding domain (RBD) of the SARS-CoV-2 spike (S) protein together with a "foldon" trimerization domain derived … BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.
Synonyms: BNT162b1 SARS-CoV-2 VaccineNKG2D-ACE2 CAR-NK Cell
go.drugbank.com/drugs/DB15727InvestigationalThe ACE2 is a receptor for SARS-Cov-2, binding to the S-protein of the viral envelope and competitively inhibiting SARS-Cov-2 infection of type II alveolar epithelial cells. … The GM-CSF acts as a neutralizer for the CAR-T cell-mediated cytokine release and neurotoxicity.
Barnidipine
go.drugbank.com/drugs/DB09227InvestigationalThe active component is composed of a single optical isomer (*3'S, 4S* configuration), which is the most potent and longest-acting of the four enantiomers [A31567]. … after a 1-year and 2-year follow-up period in 91% of the patients who had an initial response to the drug [A7842].
Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingRhein
go.drugbank.com/drugs/DB13174ExperimentalRhein is an anthraquinone metabolite of rheinanthrone and senna glycoside is present in many medicinal plants including Rheum palmatum, Cassia tora, Polygonum multiflorum, and Aloe barbadensis [A19247] … It is known to have hepatoprotective, nephroprotective, anti-cancer, anti-inflammatory, and several other protective effects.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 CYP2C9 InhibitorsRosuvastatin
go.drugbank.com/drugs/DB01098ApprovedInvestigationalfound in clinical studies to result in a 45.8% to 54.6% decreases in LDL cholesterol levels, which is about three-fold more potent than [atorvastatin]'s effects on LDL cholesterol. … as well as the need for surgical revascularization or angioplasty following a heart attack.
Mixtures: ROSUVINA LEGRAND® E 10/40, ROSUVINA LEGRAND® E 10/20Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A InhibitorsAflibercept
go.drugbank.com/drugs/DB08885ApprovedInvestigationalgamma 1 (IgG1). … [A261130] Structurally, Aflibercept is a dimeric glycoprotein with a protein molecular weight of 96.9 kilo Daltons (kDa).
Products: EYLIA® SOLUCIÓN PARA INYECCIÓN INTRAVÍTREA, ZALTRAP 100MG/4ML INFUZYONLUK KONSANTRE COZELTI İÇEREN FLAKON, 3 ADET